Syros Pharmaceuticals Inc diskutieren

folgen

a6 +

Pharma SecteurProduits

stratec stimmt der Outperform-Einschätzung der institutionellen Analysten zu

stratec stimmt am 08.01.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 28 $ zu.

Oppenheimer goes bullish on Syros Pharmaceuticals (SYRS) after they announced a research collaboration deal with Incyte (INCY). Oppenheimer's analyst assigns a buy rating and $28 price target on the stock. He had this to say about the deal:

Syros Pharmaceuticals and Incyte Corporation announced today that the companies have entered into a target discovery, research collaboration and option agreement. Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs), and Incyte will receive options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. Incyte will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets.

The companies reported the transaction is effective immediately.

Syros with an enriched pipeline of molecules to potentially service immuno-oncology indications.

Oppenheimer starts Syros Pharmaceuticals with a new Outperform rating and $13 price target.  Oppenheimer's analyst 'believes the company's lead program, SY-1425, has demonstrated compelling
clinical proof-of-concept in a biomarker-defined population of acute myeloid leukemia patients and has an opportunity for approval in multiple therapeutic settings. However, recent changes in the AML
competitive landscape, such as the approval of venetoclax, could limit uptake and prolong development timelines relative to previous estimates.' Nonetheless, the analyst 'sees SY-1425 + azacitidine as a promising combination therapy in AML and expects the company to announce updated development plans in early 2019.'